What is Hypermatrix™

Hypermatrix™ is our core multidimensional controlled‑release (CR) technology offering a flexible, polymer‑based delivery system designed for precise, time‑released drug delivery. By embedding the API into a uniform matrix or coating of one or more polymers, we gain full control over the release kinetics, ensuring the therapeutic effect occurs exactly when and where intended.

Our platform responds to the dynamic
environment of the gastrointestinal tract (GIT), releasing the drug according to the desired release profile — whether immediate, delayed, sustained, or pulsatile.

Why Hypermatrix™ Matters

Precision & Versatility
The technology allows manipulation of multiple variables (polymer type,
matrix density, coating parameters), enabling custom release profiles tailored
to drug chemistry and therapeutic needs.

Wide Applicability
Suitable for a broad range of pharmaceuticals: from small molecules to more complex APIs — and adaptable for both new drugs (e.g. NDA/505(b)(2) path) and generic controlled‑release products (e.g. ANDA path).

Efficient Development Cycle
The flexibility and robustness of Hypermatrix™ can accelerate formulation development and reduce risk, making it well‑suited for tight regulatory timelines and commercial scale‑up.

Typical Use Cases & Therapeutic Areas

Typical Use Cases & Therapeutic Areas

Hypermatrix™ is highly suitable when: The API requires controlled or sustained release to maintain therapeutic drug levels over time for improving patient compliance and reducing dosing frequency. There is a need to convert a branded immediate‑release formulation into a once‑daily or extended‑release product (life‑cycle management). Generic CR formulations are required to compete with branded products offering similar performance with efficient development timeline. Drugs targeting chronic conditions (e.g. cardiovascular, gastrointestinal, metabolic, neurology, pain) where stable plasma concentration and compliance are critical.

At Medicap Labs, we leverage Hypermatrix™ to offer:

  • Controlled-release formulation development (from early-stage formulation to commercial manufacturing).
  • Regulatory support for both ANDA (generic) and NDA (505(b)(2) or novel) pathways.
  • Flexible tailoring of release profiles based on API properties and therapeutic targets.
  • Scale-up and GMP-compliant production capabilities — ensuring reliable transition from lab to commercial batches.

Interested in exploring how Hypermatrix™ can meet your development needs? Reach out to our team to discuss your API, target release profile, and regulatory strategy.

Get Started